Safety and adverse effects associated with GLP-1 analogues.
The incretin mimetics are an emerging class of agents for the treatment of diabetes. So far, exenatide is licensed for use in the US and also became available in the UK in May 2007. Within development and Phase III trials, liraglutide may also be made available within the next 2 years. These agents enhance glucose-dependent insulin secretion and exhibit other antihyperglycaemic actions, which are of particular benefit to overweight patients with Type 2 diabetes. This article reviews the profile of adverse effects for these agents in relation to their current (exenatide) and anticipated (liraglutide) role in the management of Type 2 diabetes.
Stephens
Jeffrey W
JW
Swansea University, Diabetes Research Group, The Medical School, Swansea, UK. J.W.Stephens@Swansea.ac.uk
Bain
Stephen C
SC
D000818:Animals; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D000069450:Liraglutide; D010455:Peptides / Q000378:metabolism; D014688:Venoms / Q000378:metabolism
D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide